Comparing Microbial Genome Sequencing Platforms

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-21

Quick Answer

• Match platform choice to your specific microbial genomics application by weighing read length, throughput, accuracy, and total workflow cost against project requirements.
• Short-read platforms such as Illumina and DNBSEQ deliver high-accuracy bacterial genome assemblies, while long-read platforms resolve repetitive regions and complete genome finishing.
• Standardized bioinformatics pipelines matter as much as platform selection, since analysis pipeline choice can alter strain typing interpretations even when sequencing data is identical.

Understanding Microbial Genome Sequencing Platforms

Whole genome sequencing (WGS) has replaced conventional typing methods for genomic relatedness analysis in outbreak investigation and surveillance because it provides higher resolution and simplified workflows compared to older approaches. The sequencing platform you select determines the quality, completeness, and utility of the genomic data generated, which directly influences downstream analyses such as species identification, antimicrobial resistance gene detection, virulence factor profiling, and phylogenetic reconstruction.

The sequencing platform landscape for bacterial genomics includes several major technology families. Short-read sequencing platforms, including Illumina and BGI DNBSEQ systems, generate high-accuracy reads of approximately 150 base pairs. Long-read platforms, such as Oxford Nanopore Technologies and Pacific Biosciences, produce reads ranging from thousands to hundreds of thousands of base pairs but typically have lower per-base accuracy. Each technology family has distinct strengths and limitations that make it more or less suitable for particular microbial genomics applications.

For laboratory professionals and researchers, the practical challenge is selecting a platform that balances throughput, read length, accuracy, cost, and workflow complexity against the specific requirements of their projects. This comparison provides a structured framework for evaluating platform options based on published evidence and established laboratory practice.

Core Principles of Platform Selection

Read Length and Genome Assembly

Read length is the most fundamental parameter distinguishing sequencing platforms and has direct consequences for bacterial genome assembly. Short-read platforms generate reads of approximately 150 base pairs, which require computational assembly of overlapping reads into contiguous sequences. The quality of this assembly depends on read depth, insert size, and the complexity of the bacterial genome being sequenced.

Genome assemblies based on short-read data can achieve high completeness for most bacterial species, but repetitive regions and mobile genetic elements present challenges. The insert size of the library preparation does not significantly impact genome assembly quality according to comparative studies of bacterial genome assembly across platforms. This finding suggests that researchers can select library preparation protocols based on other factors such as cost, throughput, and compatibility with automation.

Long-read platforms produce reads that span repetitive regions and structural variants, enabling complete genome assembly without the gaps that often remain in short-read assemblies. However, the higher error rates of long-read platforms require either higher sequencing depth or hybrid assembly approaches that combine long reads with accurate short reads to polish the final assembly.

Accuracy and Error Profiles

Per-base accuracy differs substantially between platform families. Short-read platforms achieve error rates below 0.1 percent, making them suitable for applications that require high-confidence variant detection, such as antimicrobial resistance gene identification and single nucleotide variant (SNV) analysis. Long-read platforms historically had error rates of 5 to 15 percent, although recent improvements have reduced raw read error rates to approximately 1 percent for some systems.

The error profile matters as much as the overall error rate. Short-read platforms predominantly produce substitution errors, while long-read platforms produce insertion and deletion errors. These differences affect downstream analyses differently. For example, detecting small insertions or deletions in coding sequences requires platforms with low indel error rates, while substitution errors can confound phylogenetic analyses if not properly filtered.

Comparative studies of bacterial genome assembly have shown that different short-read platforms produce assemblies with distinct characteristics. One study comparing the DNBSEQ platform and Illumina HiSeq 2000 found that DNBSEQ assemblies exhibited higher completeness and fewer N bases in high GC genomes, while HiSeq 2000 assemblies exhibited higher N50 values. The majority of assembly assessment parameters, including 16S rRNA gene sequences and genome sequences, did not differ significantly between platforms. However, more insertions were detected in HiSeq 2000 genome assemblies, whereas more deletions were detected in DNBSEQ assemblies.

Throughput and Scalability

Throughput determines how many bacterial genomes can be sequenced in a single run and directly affects cost per genome and project timelines. High-throughput platforms can sequence hundreds or thousands of bacterial genomes in parallel, making them suitable for large-scale surveillance studies and population-level analyses. Lower-throughput platforms may be more appropriate for small projects or for laboratories that need rapid turnaround for individual clinical samples.

The scalability of a sequencing platform also depends on the flexibility of its run configurations. Some platforms allow partial runs or variable numbers of samples per run, which can help laboratories match throughput to demand. Automated platforms can reduce turnaround time and manual labor, as demonstrated by a study of an automated whole genome sequencing platform that reduced turnaround time by 16 to 19 hours and eliminated 3 hours of manual labor while decreasing costs by an estimated 34 to 57 percent depending on the number of isolates run.

Cost Considerations

The total cost of bacterial genome sequencing includes instrument acquisition or access fees, library preparation reagents, sequencing reagents, consumables, labor, and bioinformatics analysis. Cost per genome decreases with increasing throughput because fixed costs are distributed across more samples. However, the optimal batch size depends on the specific platform and the laboratory's sample volume.

Cost comparisons between platforms must account for the full workflow, beyond sequencing reagents. Automated platforms may have higher instrument costs but lower labor costs, making them more economical for laboratories with high sample volumes. Conversely, manual workflows may be more cost-effective for low-volume laboratories despite requiring more hands-on time.

At a Glance

Platform Comparison for Bacterial Genomics Applications

Whole Genome Assembly and Finishing

The goal of bacterial genome assembly is to reconstruct the complete genome sequence from sequencing reads. The quality of the assembly determines the reliability of all downstream analyses, including gene annotation, variant detection, and comparative genomics.

Short-read platforms can produce high-quality draft assemblies for most bacterial species. The completeness of these assemblies depends on sequencing depth, library quality, and the complexity of the genome. Comparative studies have shown that different short-read platforms produce assemblies with comparable overall quality, although specific metrics may differ. For example, one study found that DNBSEQ assemblies had higher completeness and fewer N bases in high GC genomes, while Illumina assemblies had higher N50 values. These differences were not associated with significant differences in the majority of assembly assessment parameters.

Complete genome assembly requires resolving repetitive regions and mobile genetic elements that cannot be assembled from short reads alone. Long-read platforms can span these regions, enabling the production of complete closed genomes. However, the higher error rates of long-read platforms require either high sequencing depth or hybrid assembly approaches that combine long reads with accurate short reads.

For most bacterial genomics applications, a high-quality draft assembly from short-read data is sufficient. Complete genome assembly is necessary for specific applications such as characterizing novel mobile genetic elements, resolving plasmid structures, or producing reference-quality genomes for comparative analyses.

Variant Detection and Mutation Analysis

Variant detection is a core application of bacterial genome sequencing, used for identifying single nucleotide variants, insertions, deletions, and other genetic changes associated with antimicrobial resistance, virulence, or epidemiological relatedness.

The accuracy of variant detection depends on sequencing depth, base quality, and the bioinformatics pipeline used for variant calling. Short-read platforms with high per-base accuracy are well suited for detecting single nucleotide variants and small indels. The error profile of the platform matters for detecting specific types of variants. One comparative study found that more insertions were detected in Illumina assemblies, whereas more deletions were detected in DNBSEQ assemblies, suggesting that platform-specific error profiles can affect variant detection results.

Long-read platforms can detect structural variants and resolve complex genomic rearrangements that are difficult or impossible to detect with short reads. However, the higher error rates of long-read platforms require careful filtering and validation of detected variants, particularly for small indels.

Outbreak Investigation and Strain Typing

Whole genome sequencing has become the standard method for investigating bacterial outbreaks and conducting genomic surveillance. The resolution provided by WGS enables discrimination between closely related strains that cannot be distinguished by conventional typing methods.

Core genome multi-locus sequence typing (cgMLST) is a standardized approach for comparing bacterial strains based on the allelic profiles of core genes. A comparative study of three commercial cgMLST pipelines found high concordance for differentiating clustered from non-clustered isolate pairs. The concordance with one reference pipeline was 100 percent for one platform and 99.5 percent for another overall. However, the study also found that one pipeline showed significantly greater allelic distances than the other two among clustered isolate pairs, indicating that the choice of analysis pipeline can affect the interpretation of strain relatedness.

The choice of sequencing platform can affect cgMLST results through differences in assembly quality and variant detection. However, the high concordance observed across platforms suggests that platform choice has less impact on typing results than the choice of analysis pipeline. This finding supports the use of standardized analysis pipelines for comparing results across laboratories and over time.

Metagenomics and Mixed Samples

Metagenomic sequencing involves sequencing DNA from complex microbial communities without prior culture. This approach is used for characterizing the microbiome, detecting pathogens directly from clinical samples, and monitoring antimicrobial resistance genes in environmental samples.

Short-read platforms are the most commonly used for metagenomic sequencing due to their high accuracy and throughput. The choice of platform can affect metagenomic results through differences in error profiles and biases. One comparative study found that mapping to metagenome data did not differ significantly between DNBSEQ and Illumina platforms, suggesting that both platforms produce comparable results for metagenomic applications.

Long-read platforms are increasingly used for metagenomics because they can resolve full-length genes and operons, providing more complete information about the functional potential of microbial communities. However, the higher error rates of long-read platforms can complicate taxonomic classification and gene annotation.

Antimicrobial Resistance Gene Detection

Detecting antimicrobial resistance genes in bacterial genomes is a critical application of WGS for clinical and public health purposes. The accuracy of resistance gene detection depends on the completeness of the genome assembly and the quality of the reference databases used for annotation.

Short-read platforms with high accuracy are well suited for resistance gene detection because they can reliably identify genes and mutations associated with resistance. The completeness of the assembly is important for detecting genes located in repetitive regions or on mobile genetic elements that may be incompletely assembled from short reads.

Long-read platforms can resolve the genomic context of resistance genes, including their location on plasmids or transposons, which is important for understanding the potential for horizontal gene transfer. However, the higher error rates of long-read platforms require careful validation of resistance gene predictions.

The global context of antimicrobial resistance surveillance is provided by the World Health Organization, which defines antimicrobial resistance as a global health threat and supports surveillance and stewardship efforts. Whole genome sequencing is a key tool for antimicrobial resistance surveillance because it enables the detection of resistance genes and the tracking of resistant strains across geographic regions and over time.

Practical Workflow for Platform Selection

Step 1: Define Project Requirements

Before evaluating specific platforms, define the requirements of your microbial genomics project. Consider the following questions:

• What is the primary application: genome assembly, variant detection, outbreak typing, metagenomics, or resistance gene detection?
• How many samples will be sequenced, and over what time period?
• What is the required turnaround time from sample to results?
• What is the budget for instrument access, reagents, and labor?
• What bioinformatics resources are available for data analysis?

Document these requirements in a project specification that can be used to evaluate platform options objectively.

Step 2: Evaluate Platform Specifications

Compare platform specifications against your project requirements. Key specifications to evaluate include:

• Read length and read type (single-end, paired-end, or long-read)
• Throughput per run and per day
• Per-base accuracy and error profile
• Library preparation requirements and compatibility with automation
• Instrument cost, reagent cost, and cost per genome
• Bioinformatics support and compatibility with analysis pipelines

Request demonstration data from platform vendors and analyze it with your own bioinformatics pipelines to assess real-world performance.

Step 3: Assess Workflow Integration

Evaluate how each platform integrates with your existing laboratory workflow. Consider:

• Sample preparation requirements and compatibility with your current DNA extraction methods
• Automation options and the potential for reducing manual labor
• Training requirements for laboratory staff
• Data management and storage requirements
• Quality control procedures and metrics

The American Society for Microbiology provides professional education and laboratory practice resources that can help laboratories assess workflow integration and implement best practices for microbial genomics.

Step 4: Conduct a Pilot Study

Before committing to a platform, conduct a pilot study using a small set of well-characterized reference strains. Sequence the same samples on candidate platforms and compare:

• Assembly quality metrics such as N50, completeness, and number of contigs
• Variant detection results against known reference sequences
• Typing results using standardized analysis pipelines
• Reproducibility across replicate runs
• Turnaround time and labor requirements

Use authenticated reference strains from a culture collection such as the American Type Culture Collection to ensure that pilot results are comparable across laboratories and platforms.

Step 5: Calculate Total Cost of Ownership

Calculate the total cost of ownership for each platform option, including:

• Instrument acquisition or access fees
• Library preparation reagents and consumables
• Sequencing reagents and flow cells
• Labor costs for sample preparation, sequencing, and data analysis
• Bioinformatics infrastructure and personnel
• Quality control and validation costs
• Maintenance and service contracts

Compare costs across platforms at your expected sample volume to identify the most economical option for your specific use case.

Step 6: Document and Review

Document the platform selection process, including the evaluation criteria, pilot study results, and cost analysis. Review the decision with stakeholders, including laboratory staff, bioinformatics personnel, and project sponsors. Establish a process for periodic review of platform performance and for evaluating new platform options as they become available.

Decision Matrix for Platform Selection

Records and Measurements

Key Performance Metrics

Track the following performance metrics for your sequencing platform to monitor quality and identify problems:

• Sequencing depth and coverage uniformity across samples
• Base quality scores and error rates
• Assembly quality metrics including N50, completeness, and number of contigs
• Variant detection concordance with reference methods
• Turnaround time from sample receipt to results
• Failure rates and reasons for failed runs
• Cost per genome at different batch sizes

Record these metrics for each sequencing run and review them regularly to identify trends or emerging problems.

Quality Control Records

Maintain quality control records for each sequencing run, including:

• DNA extraction quality metrics such as concentration and purity
• Library preparation quality metrics such as fragment size and concentration
• Sequencing run metrics such as cluster density and quality scores
• Assembly quality metrics and comparison to reference genomes
• Results of control samples included in each run

The Bacteriological Analytical Manual from the U.S. Food and Drug Administration provides context for quality control in food microbiology laboratories, including the importance of validated methods and quality assurance procedures.

Sample and Data Tracking

Implement a system for tracking samples from receipt through sequencing to data analysis. Each sample should have a unique identifier that links to:

• Source information and collection date
• DNA extraction and library preparation records
• Sequencing run information and quality metrics
• Assembly and analysis results
• Storage location for DNA and sequence data

This tracking system is essential for reproducibility and for investigating problems when they occur.

Common Failure Patterns and Troubleshooting

Low Sequencing Depth

Low sequencing depth can result from insufficient DNA input, poor library preparation, or problems with the sequencing run. Symptoms include incomplete genome assemblies, low coverage in GC-rich regions, and unreliable variant detection.

Troubleshooting steps include verifying DNA concentration and quality before library preparation, checking library concentration and fragment size, and reviewing sequencing run metrics to identify the cause of low output.

High Error Rates

Elevated error rates can result from poor base calling, contamination, or problems with the sequencing chemistry. Symptoms include high numbers of variants in regions that should be conserved, difficulty assembling repetitive regions, and discordant results between replicate samples.

Troubleshooting steps include reviewing base quality scores, checking for contamination using control samples, and verifying that the correct sequencing chemistry and protocols were used.

Assembly Gaps and Fragmentation

Fragmented assemblies with many contigs can result from insufficient sequencing depth, problems with library preparation, or the presence of repetitive regions that cannot be resolved with short reads.

Troubleshooting steps include increasing sequencing depth, optimizing library preparation to achieve appropriate insert sizes, and considering long-read sequencing for genomes with complex repetitive regions.

Discordant Typing Results

Discordant results between different analysis pipelines can occur even when the same sequencing data is used. A comparative study of cgMLST pipelines found that one pipeline showed significantly greater allelic distances than others among clustered isolate pairs, indicating that the choice of analysis pipeline can affect the interpretation of strain relatedness.

Troubleshooting steps include verifying that the same analysis pipeline is used for all samples in a study, documenting pipeline versions, and validating results using reference strains with known relationships.

Batch Effects

Batch effects can occur when samples are sequenced in different runs or on different platforms, introducing systematic differences that are not related to biological variation. Symptoms include clustering of samples by sequencing run instead of by biological characteristics.

Troubleshooting steps include randomizing samples across runs, including control samples in each run, and using statistical methods to detect and correct for batch effects.

Biosafety and Laboratory Practice

Risk Assessment

All work with bacterial pathogens requires a risk assessment that considers the hazard level of the organisms being studied, the procedures being performed, and the laboratory facilities and equipment available. The Biosafety in Microbiological and Biomedical Laboratories manual from the CDC and NIH provides guidance on risk assessment, containment, decontamination, and laboratory biosafety principles.

For sequencing applications, the risk assessment should consider:

• The pathogenicity of the organisms being sequenced
• The potential for aerosol generation during sample preparation
• The need for containment facilities and practices
• Decontamination procedures for equipment and waste

Sample Handling and Containment

Bacterial samples for sequencing should be handled according to the biosafety level appropriate for the organisms being studied. Inactivated samples may be handled at lower containment levels, but the inactivation method must be validated to ensure complete killing of the organisms.

DNA extraction procedures should be performed in a manner that minimizes the risk of contamination and exposure. This includes using appropriate personal protective equipment, working in a biosafety cabinet when necessary, and following established decontamination procedures.

Data Security and Privacy

Genomic data from bacterial pathogens may have public health implications and should be handled according to applicable regulations and institutional policies. This includes:

• Secure storage of sequence data and associated metadata
• Controlled access to data that could identify individuals or institutions
• Compliance with data sharing requirements for public health surveillance
• Documentation of data handling procedures and access controls

The NCBI Pathogen Detection resource provides a platform for sharing pathogen genomic data for public health surveillance, with standardized analysis and reporting.

Limitations and Evidence Gaps

Platform Comparisons Are Context-Specific

Published comparisons of sequencing platforms are conducted under specific conditions that may not reflect your laboratory's workflow, sample types, or analysis pipelines. Results from one study may not generalize to other settings, particularly when different library preparation protocols, sequencing chemistries, or bioinformatics pipelines are used.

Rapid Technology Evolution

Sequencing platforms evolve rapidly, with improvements in read length, accuracy, throughput, and cost occurring frequently. Published comparisons may not reflect the current performance of a platform, and specifications provided by vendors should be validated through pilot studies.

Analysis Pipeline Effects

The choice of bioinformatics pipeline can have as much impact on results as the choice of sequencing platform. A comparative study of cgMLST pipelines found significant differences in allelic distances between pipelines, even when the same sequencing data was used. This finding highlights the importance of standardizing analysis pipelines for comparing results across studies and laboratories.

Reference Database Limitations

The accuracy of resistance gene detection and other annotation-based analyses depends on the completeness and quality of reference databases. Gaps in reference databases can lead to false-negative results, while errors in reference sequences can lead to false-positive results.

Validation Requirements

Laboratories implementing WGS for clinical or regulatory applications must validate their methods according to applicable standards. The Clinical and Laboratory Standards Institute provides standards for antimicrobial susceptibility testing and related microbiology applications, which may include guidance on validating WGS-based methods.

Professional Escalation Criteria

When to Consult a Bioinformatics Specialist

Consult a bioinformatics specialist when:

• Assembly quality metrics are consistently below expected thresholds
• Variant detection results are discordant with reference methods
• You need to implement new analysis pipelines or compare results across pipelines
• You are planning large-scale sequencing projects that require significant computational resources

When to Consult a Biosafety Officer

Consult a biosafety officer when:

• You are working with organisms that require containment levels beyond your current facilities
• You are implementing new procedures that may create aerosols or other exposure hazards
• You need to validate inactivation methods for samples that will be processed at lower containment levels
• You are uncertain about the appropriate biosafety level for your work

When to Consult a Clinical Microbiology Specialist

Consult a clinical microbiology specialist when:

• You are implementing WGS for clinical diagnostic or outbreak investigation purposes
• You need to validate WGS results against conventional typing methods
• You are interpreting WGS results for patient care or public health decisions
• You need guidance on regulatory requirements for WGS-based testing

When to Consult a Public Health Authority

Consult a public health authority when:

• You identify potential outbreaks or clusters of infections
• You detect novel resistance mechanisms or unusual resistance patterns
• You need to share genomic data for public health surveillance
• You are uncertain about reporting requirements for notifiable conditions

Building a Platform Validation Protocol for Cross-Laboratory Reproducibility

Why Validation Protocols Matter for Platform Selection

The decision to adopt a sequencing platform extends beyond comparing specifications and running pilot studies. A structured validation protocol provides the evidence needed to confirm that a platform performs reliably in your specific laboratory conditions, with your sample types, and through your chosen analysis pipelines. Published comparisons of sequencing platforms are conducted under controlled conditions that may not reflect your workflow, and results from one study may not generalize to other settings. A formal validation protocol generates local evidence that vendor specifications and published benchmarks cannot provide.

The need for structured validation is particularly acute in microbial genomics because the consequences of platform-related errors can affect outbreak investigations, antimicrobial resistance surveillance, and clinical decisions. The World Health Organization identifies antimicrobial resistance as a global health threat requiring reliable surveillance data, and whole genome sequencing is a key tool for tracking resistant strains. If platform-specific errors are not characterized during validation, they can be misinterpreted as biological variation in downstream analyses.

Defining Validation Objectives and Acceptance Criteria

Before beginning validation, define what the platform must achieve in your specific context. Validation objectives should be derived from the intended applications of the platform, not from generic performance claims. For example, if the platform will be used for outbreak investigation with core genome multi-locus sequence typing (cgMLST), the validation should focus on the platform's ability to produce data that yields concordant typing results with established methods.

Establish acceptance criteria before collecting validation data. These criteria should be quantitative and tied to the intended use of the data. Examples of acceptance criteria include:

• Minimum assembly completeness of 95 percent for reference strains with known genome sequences
• Maximum of 10 assembly contigs for a standard bacterial genome at a defined sequencing depth
• Variant detection concordance of at least 99 percent with Sanger sequencing or a reference platform for a defined set of variants
• cgMLST allelic distance of zero between replicate sequencing runs of the same DNA sample
• Turnaround time from DNA extraction to assembled genome within a defined number of hours

The Clinical and Laboratory Standards Institute provides standards-based context for validation in microbiology laboratories, particularly for antimicrobial susceptibility testing. While these standards focus on phenotypic testing, the principles of validation, verification, and quality control apply to WGS-based methods as well.

Selecting Validation Reference Materials

The choice of reference materials determines the strength of the validation evidence. Use authenticated biological materials from a recognized culture collection such as the American Type Culture Collection whenever possible. Authenticated strains have documented provenance, known genome sequences, and established phenotypic characteristics that can be used to verify sequencing results.

Select reference strains that represent the range of challenges your platform will encounter in routine use. Consider including:

• A standard laboratory strain with a well-characterized reference genome for baseline assembly and variant detection assessment
• A strain with high GC content to assess coverage uniformity and assembly completeness in GC-rich regions
• A strain with known repetitive elements or mobile genetic elements to assess the platform's ability to resolve complex genomic regions
• A strain with known antimicrobial resistance genes to verify resistance gene detection
• A strain with a complete closed reference genome to assess assembly accuracy against a gold standard

For outbreak investigation applications, include a set of epidemiologically related strains with known relationships. The NCBI Pathogen Detection resource provides access to pathogen genomic data and can help identify well-characterized strain sets for validation purposes.

Designing the Validation Study

The validation study should be designed to assess both accuracy and reproducibility. Accuracy refers to how closely the sequencing results match the known characteristics of the reference materials. Reproducibility refers to the consistency of results across replicate runs, operators, and batches.

A minimum validation design includes:

• Three biological replicates of each reference strain, where each replicate is an independent DNA extraction from the same strain
• Two technical replicates of each biological replicate, where each technical replicate is an independent library preparation from the same DNA extract
• Sequencing of all replicates in at least two separate runs to assess run-to-run variability
• Inclusion of a negative control in each run to detect contamination

This design allows assessment of variation at each level of the workflow: biological variation, DNA extraction variation, library preparation variation, and sequencing run variation. The Bacteriological Analytical Manual from the U.S. Food and Drug Administration provides context for quality assurance in microbiological methods, including the importance of replicate testing and control samples.

Establishing the Analysis Pipeline Before Validation

The analysis pipeline must be fixed before validation begins. Changing the pipeline during validation confounds the interpretation of results, because differences between runs could be due to either the platform or the pipeline. Document the exact versions of all software used, including assembly tools, quality assessment tools, variant callers, and typing pipelines.

The choice of analysis pipeline can significantly affect results even when the same sequencing data is used. A comparative study of three commercial cgMLST pipelines found that one pipeline showed significantly greater allelic distances than the others among clustered isolate pairs, even though concordance for differentiating clustered from non-clustered isolates was high. This finding demonstrates that pipeline selection is as important as platform selection for typing applications.

For validation purposes, consider using at least two independent analysis approaches to assess whether results are robust to pipeline choice. For example, assemble the data with two different assemblers and compare the resulting assemblies. If the assemblies differ substantially, investigate whether the differences are due to platform-specific error profiles or to assembler-specific behavior.

Executing the Validation Study

Execute the validation study according to the predefined design, documenting all steps and observations. Record the following for each sample:

• DNA extraction method and quality metrics including concentration, purity, and integrity
• Library preparation method and quality metrics including fragment size distribution and concentration
• Sequencing run parameters including flow cell type, chemistry version, and run duration
• Raw data quality metrics including read counts, read length, and base quality scores
• Assembly quality metrics including N50, completeness, and number of contigs
• Variant detection results compared to the reference genome
• Typing results using the standardized pipeline

The American Society for Microbiology provides professional education resources on laboratory practice that emphasize the importance of documentation and quality assurance in microbiology workflows.

Analyzing Validation Results

Analyze the validation data against the predefined acceptance criteria. For each criterion, determine whether the platform met the threshold and document the evidence. If a criterion was not met, investigate the cause before deciding whether to adjust the criterion or reject the platform.

For assembly quality, compare the observed metrics to the known characteristics of the reference genomes. A high-quality assembly of a standard bacterial genome should have high completeness and a small number of contigs. The presence of many small contigs may indicate problems with sequencing depth, library preparation, or the presence of repetitive regions that cannot be resolved with short reads.

For variant detection, compare the detected variants to the known variants in the reference genome. A comparative study of the DNBSEQ platform and Illumina HiSeq 2000 found that more insertions were detected in Illumina assemblies, whereas more deletions were detected in DNBSEQ assemblies. This finding suggests that platform-specific error profiles can affect variant detection results, and validation should assess whether such differences are present in your data.

For typing applications, compare the cgMLST results across replicates and across platforms if you are comparing multiple platforms. The concordance between platforms should be high when the same analysis pipeline is used. A study comparing an automated whole genome sequencing platform to a manual approach found that 222 of 224 isolate sequences showed concordant isolate groupings, demonstrating that different platforms can produce equivalent typing results when properly validated.

Documenting the Validation Report

The validation report should provide a complete record of the validation study, including:

• Validation objectives and acceptance criteria
• Description of reference materials and their provenance
• Detailed methods for DNA extraction, library preparation, and sequencing
• Analysis pipeline versions and parameters
• Results for each acceptance criterion with supporting data
• Discussion of any criteria that were not met and the investigation findings
• Conclusions about the platform's suitability for the intended applications
• Recommendations for ongoing quality control and monitoring

The report should be reviewed by stakeholders including laboratory staff, bioinformatics personnel, and project sponsors. The Biosafety in Microbiological and Biomedical Laboratories manual from the CDC and NIH provides context for documenting risk assessments and laboratory procedures, which should be referenced in the validation report where relevant.

Implementing Ongoing Quality Monitoring

Validation is not a one-time activity. After the platform is implemented, establish ongoing quality monitoring to detect changes in platform performance over time. This monitoring should include:

• Inclusion of a control strain in each sequencing run to track assembly quality and variant detection over time
• Tracking of key quality metrics in a run log, including read counts, quality scores, and assembly metrics
• Periodic review of quality metrics to identify trends or shifts that may indicate emerging problems
• Revalidation when significant changes are made to the platform, including chemistry updates, software upgrades, or changes to library preparation protocols

The Bacteriological Analytical Manual emphasizes the importance of ongoing quality assurance in microbiological methods, and the same principles apply to sequencing-based methods.

Common Validation Pitfalls and How to Avoid Them

Several common pitfalls can undermine the validity of a platform validation study. Being aware of these pitfalls before starting can help you design a more robust validation.

The first pitfall is using too few reference strains. A validation based on a single strain provides limited evidence about platform performance across the diversity of bacterial genomes. Include strains that represent the range of GC content, genome size, and genomic complexity expected in your routine samples.

The second pitfall is inadequate replication. Without sufficient replicates, you cannot distinguish between random variation and systematic platform effects. The validation design should include enough replicates to provide statistical power for detecting meaningful differences.

The third pitfall is changing the analysis pipeline during validation. This confounds the interpretation of results and makes it impossible to determine whether observed differences are due to the platform or the pipeline. Fix the pipeline before starting validation and document all versions.

The fourth pitfall is ignoring batch effects. Samples sequenced in different runs can show systematic differences that are not related to biological variation. The validation design should include samples sequenced across multiple runs to assess run-to-run variability.

The fifth pitfall is failing to document negative results. If a platform does not meet an acceptance criterion, document the finding and investigate the cause. Negative results provide valuable information about platform limitations and can inform decisions about whether the platform is suitable for specific applications.

Integrating Validation Results into Platform Selection

The validation results should be integrated into the overall platform selection decision alongside the technical specifications, cost analysis, and workflow considerations. A platform that performs well in published comparisons but fails validation in your laboratory should not be selected, regardless of its theoretical advantages. Conversely, a platform that meets all acceptance criteria in validation may be suitable even if published comparisons suggest limitations in specific applications.

The validation protocol also provides a framework for comparing multiple platforms objectively. By running the same reference materials through the same validation design on each candidate platform, you can generate directly comparable evidence about performance in your specific context. This approach is more reliable than comparing results across different studies that used different reference materials, different analysis pipelines, and different quality metrics.

Records and Measurements for Validation

Maintain comprehensive records of the validation study, including:

• Validation protocol and any amendments made during the study
• Raw sequencing data and processed data for all replicates
• Quality metrics for each sequencing run
• Assembly files and variant call files for all samples
• Analysis pipeline versions and configuration files
• Validation report and approval documentation

These records serve multiple purposes. They provide evidence of the platform's performance for regulatory or accreditation purposes. They establish a baseline for ongoing quality monitoring. They allow retrospective investigation of problems that may emerge during routine use. And they provide a reference for future validation studies if the platform or analysis pipeline is changed.

The American Type Culture Collection provides authenticated reference strains that can be used for validation and for ongoing quality control. Using the same reference strains for validation and for routine quality monitoring allows direct comparison of performance over time.

Professional Escalation Criteria for Validation

Consult a bioinformatics specialist when:

• Validation results show discordance between replicate samples that cannot be explained by known sources of variation
• Assembly quality metrics are consistently below expected thresholds for reference strains
• Variant detection results differ substantially between analysis pipelines
• You need to design a validation study for a novel application or sample type

Consult a biosafety officer when:

• Validation involves working with pathogens that require containment levels beyond your current facilities
• You are implementing new sample preparation procedures that may create aerosols or other exposure hazards
• You need to validate inactivation methods for samples that will be processed at lower containment levels

Consult a clinical microbiology specialist when:

• Validation results will be used to support clinical diagnostic applications
• You need to compare WGS results to conventional typing methods for validation purposes
• You are interpreting validation results for regulatory or accreditation purposes

Consult a public health authority when:

• Validation involves strains that are part of an active outbreak investigation
• You detect unexpected resistance mechanisms or unusual resistance patterns during validation
• You need guidance on data sharing requirements for validation data that includes pathogen genomic sequences

Frequently Asked Questions

What is the difference between short-read and long-read sequencing platforms?

Short-read platforms generate reads of approximately 150 base pairs with high accuracy, making them suitable for most bacterial genomics applications including genome assembly, variant detection, and typing. Long-read platforms generate reads of thousands to hundreds of thousands of base pairs with lower per-base accuracy, enabling complete genome assembly and resolution of repetitive regions and structural variants. The choice between them depends on the specific requirements of your project, including the need for complete genomes versus high-throughput draft assemblies.

How does platform choice affect bacterial genome assembly quality?

Platform choice affects assembly quality through differences in read length, error profiles, and sequencing biases. Comparative studies have shown that different short-read platforms produce assemblies with comparable overall quality, although specific metrics may differ. For example, one platform may produce assemblies with higher completeness while another produces assemblies with higher N50 values. These differences are generally not associated with significant differences in the majority of assembly assessment parameters.

Can I use different sequencing platforms for the same project?

Using different platforms within the same project is possible but requires careful consideration of potential batch effects and platform-specific biases. If you must use multiple platforms, include control samples on each platform and use statistical methods to detect and correct for systematic differences. Standardizing your analysis pipeline across all samples is essential for comparing results.

How does the choice of analysis pipeline affect typing results?

The choice of analysis pipeline can significantly affect typing results, even when the same sequencing data is used. A comparative study of cgMLST pipelines found that one pipeline showed significantly greater allelic distances than others among clustered isolate pairs, which could affect the interpretation of strain relatedness. Use the same pipeline for all samples in a study and document pipeline versions to ensure comparability.

What is the minimum sequencing depth for bacterial genome assembly?

The minimum sequencing depth for bacterial genome assembly depends on the platform, the complexity of the genome, and the intended use of the assembly. Higher depth generally improves assembly quality, particularly for genomes with repetitive regions or extreme GC content. Pilot studies using reference strains can help determine the appropriate depth for your specific application.

How do I validate a new sequencing platform for clinical use?

Validating a new sequencing platform for clinical use requires comparing its performance against established methods using well-characterized reference strains. Include samples with known variants, resistance genes, and epidemiological relationships to assess the platform's ability to detect these features. Document the validation results and establish quality control procedures before using the platform for clinical samples.

What quality control samples should I include in each sequencing run?

Include positive and negative controls in each sequencing run to monitor performance and detect contamination. Positive controls should be well-characterized reference strains with known genome sequences, while negative controls should contain no DNA to detect contamination. Track quality metrics for control samples over time to identify trends or emerging problems.

How do I compare costs between sequencing platforms?

Compare the total cost of ownership for each platform, including instrument access, reagents, consumables, labor, bioinformatics, and maintenance. Calculate cost per genome at your expected sample volume, since cost per genome decreases with increasing throughput. Automated platforms may have higher instrument costs but lower labor costs, making them more economical for high-volume laboratories.

Related Bacteriology Guides

• Avian Influenza Treatments: Current Antiviral and Supportive Therapy Options
• Poultry Diseases Caused by Bacteria: Pathogenesis and Management Strategies
• Chicken Food Bacteria: Pathogens in Poultry Feed and Their Impact on Flock Health
• Bacterial Diseases in Chickens: A Comprehensive Veterinary Reference
• Bovine Mastitis Caused by Staphylococcus aureus: Diagnostic Approaches and One Health Implications

References and Further Reading

• Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
• Microbiology Resources. American Society for Microbiology.
• Antimicrobial Resistance. World Health Organization.
• Bacteriological Analytical Manual. U.S. Food and Drug Administration.
• Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute.
• Culture Collections. American Type Culture Collection.
• NCBI Pathogen Detection. National Center for Biotechnology Information.
• Comparison of core genome multi-locus sequencing typing pipelines for hospital outbreak detection of common bacterial pathogens.. Journal of clinical microbiology, 2025.
• Comparison of the DNBSEQ platform and Illumina HiSeq 2000 for bacterial genome assembly.. Scientific reports, 2024.
• Automated whole genome sequencing platform for bacterial strain typing in clinical microbiology laboratories.. Journal of clinical microbiology, 2025.
• Standards for sequencing viral genomes in the era of high-throughput sequencing.. mBio, 2014.

This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.